Skip to main content
TKPHF logo

Takeda Pharmaceutical Company Limited (TKPHF) Stock Price & Analysis

Takeda Pharmaceutical Company Limited (TKPHF) — price $43.05 (-1.24%), as of the Nov 19, 2026 trading session; market cap $68.8B.

Educational signal · not a buy or sell recommendation · How to read this

$43.05 −$0.54 (-1.24%) Market Cap $68.8B

Takeda Pharmaceutical Company Limited · TKPHF · Healthcare · Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • TEVA · Teva Pharmaceutical Industries Limited · 57 /100
  • ZTS · Zoetis Inc. · 87 /100
  • VTRS · Viatris Inc. · 35 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$43.05
Change on the day-1.24%
52-week range$27.63–$43.59
Market capitalisation$68.8B—
Price / earnings (trailing)28.08
Shares traded on the day100
Beta (volatility vs the S&P 500)0.09

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $26, high $43, latest $43. $43 $26 high $43 Oct 17, 2025 Nov 19, 2026 · $43 $29Oct 17, 2025$28Oct 31, 2025$28Nov 14, 2025$29Nov 28, 2025$29Dec 12, 2025$30Dec 26, 2025$32Jan 9, 2026$31Jan 23, 2026$38Feb 6, 2026$37Feb 20, 2026$35Mar 6, 2026$36Mar 20, 2026$35Apr 2, 2026$35Apr 17, 2026$34May 1, 2026$33May 15, 2026$30May 29, 2026$34Jun 12, 2026$31Jun 26, 2026$35Jul 10, 2026$31Jul 24, 2026$36Aug 7, 2026$36Aug 21, 2026$37Sep 4, 2026$38Sep 18, 2026$37Oct 2, 2026$39Oct 16, 2026$42Oct 30, 2026$43Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Takeda Pharmaceutical Company (TKPHF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 12, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Weak
ROE Weak
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Takeda Pharmaceutical Company (TKPHF), and what does it report?

Short answer

Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 1-1, Nihonbashi-Honcho 2-Chome, Chuo-KU, Tokyo, M0, 103-8668. It employs 47,029 people and is led by Julie So-Young Kim. In Q2 FY2026 it reported revenue of ¥1187.10B and net income of ¥192.43B. The market values it at $68.8B.

2 · Latest results

What do the latest results show for Takeda Pharmaceutical Company (TKPHF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of ¥1187.10B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026¥1187.10B¥192.43B¥119.91 (diluted)
Q1 FY2026¥1219.90B¥113.20B¥70.54 (diluted)
Q4 FY2025¥1101.43B-¥24.47B-¥15.66 (diluted)
Q3 FY2025¥1192.74B¥103.73B¥64.73 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Takeda Pharmaceutical Company (TKPHF)?

Short answer · as of

The distress and quality screens read Altman Z 1.43 · Piotroski F 6. Trailing ratios: ROE 0.6% · ROA 3.3% · current ratio 1.15.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.43 sits in the distress zone (elevated bankruptcy risk).
  • Rich valuation — a P/E of 28.08 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Takeda Pharmaceutical Company (TKPHF)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $4.66T · EPS 134.76 · 16 analysts.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$4.66T
EPS estimate
$134.76

Measured against a quoted price of $43.05 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TKPHF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TKPHF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Takeda Pharmaceutical Company Healthcare Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the TKPHF research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is TKPHF a good stock to buy?

Stock Expert AI does not rate TKPHF buy, sell or hold. Takeda Pharmaceutical Company Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TKPHF stock price today?

The last price recorded for Takeda Pharmaceutical Company Limited (TKPHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for TKPHF?

Key risks for Takeda Pharmaceutical Company Limited include regulatory challenges that could delay drug approvals and impact market entry. Additionally, the company faces ongoing competition from other biopharmaceutical firms, which may pressure pricing and market share. Lastly, the potential for changes in healthcare policies could affect revenue and profitability.

What are the key factors to evaluate for TKPHF?

Evaluate TKPHF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The company’s innovative therapies in this area, particularly in immuno-oncology, position it well against competitors, potentially capturing a larger market share as demand for effective cancer treatments continues to rise. Not financial advice.

How frequently does TKPHF data refresh on this page?

TKPHF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TKPHF's recent stock price performance?

Takeda Pharmaceutical Company Limited (TKPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence with a long history in the pharmaceutical industry. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TKPHF overvalued or undervalued right now?

The trailing P/E of Takeda Pharmaceutical Company Limited (TKPHF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research TKPHF before investing?

Before investing in Takeda Pharmaceutical Company Limited (TKPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.